Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Biocon Biologics Ltd updates on Semglee in USA

Posted On: 2021-10-22 11:49:40 (Time Zone: IST)


Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. has announced that Express Scripts, a leading pharmacy benefit management organization in the US, will list Biocon Biologics interchangeable biosimilar Insulin Glargine (Semglee*), which will be commercialized by Viatris, as a preferred glargine brand on its National Preferred Formulary® (NPF), which includes more than 28 million lives.

Broad coverage of Semglee® by Express Scripts will help ensure that the many patients on its network who need Insulin Glargine may receive the full benefits of and access to treatment with lower or maintained out-of-pocket costs.

Biocon Biologics co-developed Semglee with Viatris and together they are committed to improving patients' access to sustainable, high-quality and affordable biosimilars. As part of this commitment, Viatris will soon commercialize two versions of our landmark Insulin Glargine injection, the first-ever interchangeable biosimilar approved by the U.S. Food and Drug Administration (FDA): Semglee® (insulin glargine-yfgn) injection, a branded interchangeable product, and Insulin Glargine (insulin glargine-yfgn) injection, an authorized interchangeable biosimilar. Both products will be available in pen and vial presentations and are interchangeable for the reference brand, Lantus®. Semglee will also be included in Express Scripts' Patient Assurance Program.

This dual product approach is intended to ensure that this historic interchangeable biosimilar insulin glargine can reach as many patients as possible regardless of financial circumstances, insurance or channel.

Commenting on this marquee development, Dr Arun Chandavarkar, Managing Director, Biocon Biologics said: "The inclusion of our interchangeable biosimilar insulin glargine in Express Scripts' National Preferred Formulary® (NPF) in the U.S. is a major milestone for Biocon Biologics. It furthers our mission of enabling affordable access to quality insulins to a large number of patients. We expect our partner to commercialize the product in the U.S. by end of the year and formulary coverage to begin in Jan 2022, making it an important growth driver for Biocon Biologics."

"We believe adoption of biosimilars through PBMs like Express Scripts, will drive down the high cost of biologics therapy for chronic diseases like diabetes. Our biosimilar Insulin Glargine has the potential to bring significant cost savings for patients, employers and PBMs," he added.

In July 2021, the U.S. Food and Drug Administration (FDA) had approved our biosimilar Insulin Glargine-yfgn injection (Semglee®) as the first interchangeable biosimilar product under the 351(k) regulatory pathway, endorsing our scientific excellence and robust quality comparability data.

Semglee* (insulin glargine-yfgn) Injection and Insulin Glargine-yfgn Injection will be available in pharmacies before the end of the year, and further details related to our partner Viatris' access programs, which aim to ensure that as many patients as possible will benefit from the product, will be available at that time.

The Express Scripts formulary change, including coverage of Semglee* (insulin glargineyfgn) on NPF, will occur effective January 1, 2022.

Express Scripts, Inc. is one of the largest PBMs in North America, providing services to thousands of client groups, including managed-care organizations, insurance carriers, employers, third-party administrators, public sector, workers compensation, and union sponsored benefit plans.

Pharmacy benefit managers, or PBMs, are companies that manage prescription drug benefits on behalf of health insurers, Medicare Part D drug plans, large employers, and other payers.

Shares of Biocon Limited was last trading in BSE at Rs. 345.10 as compared to the previous close of Rs. 341.75. The total number of shares traded during the day was 121388 in over 3006 trades.

The stock hit an intraday high of Rs. 349.00 and intraday low of 338.00. The net turnover during the day was Rs. 41678053.00.

*Biosimilar insulin glargine co-developed with Viatris


Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Anjani Portland Cement Limited receives demand notice for Rs. 16.71 crore from power distribution company

India's biggest annual conference on eye surgery IIRSI 2021 inaugurated

Brightcom Group Ltd to consider shares allotment for acquisition

Alankit Ltd board to consider fund raising on Dec 8, 2021

GSS Infotech Ltd approves fund raising, acquisition proposal

Bank of India unveils 'Azadi ka Amrit Mahotsav' at all its branches across India

Nxtdigital Ltd approves allotment of 96,20,463 Rights Equity Shares

IITL - Nimbus The Palm Village surrenders unutilized land to YEIDA

Carborundum Universal Ltd subsidiary to acquire company in Germany

Polo Queen Industrial and Fintech Limited updates on new project

Arihant Capital Markets Ltd to divest SPA Electrum Portfolio Managers Ltd

Yash Innoventures Ltd purchases land at Kolet, Sanand to carry out Residential Plotting Scheme

H G Industries Ltd becomes subsidiary of Greenlam Industries Limited

Steelcast Ltd announces Long-term Supply Agreement with large OEM for North American Rail-Road Industry

Sangam India Ltd forms subsidiary

Cheviot Company Ltd board approves buyback at Rs. 1725 per share

Safari Industries India Ltd's subsidiary to purchase land and property at Panchmahal district

Narayana Hrudayalaya Ltd to set up Multi-Speciality Hospital in Ludhiana in partnership with Ritesh Properties & Industries Limited

Mahalaxmi Rubtech Ltd to seek listing in NSE

Fedders Electric and Engineering Ltd allots shares to IM+ Capitals Ltd

Celebrity Fashions Limited to consider fund raising on Dec 8, 2021

Tech Mahindra acquires 100% stake in Activus Connect

INOX Wind Ltd allots NCPRPS

PNB Housing Finance appoints Amit Singh as Chief People Officer

Lupin and Biomm Enter into a Distribution and Marketing Agreement for Pegfilgrastim in Brazil

Maitri Enterprises Ltd board to consider preferential issue

NMDC Ltd board recomends interim dividend of Rs. 9.01

Lloyds Metals and Energy Ltd announces extension of mining lease for another 30 years

GAIL opens new round for submission of proposals from Start-Ups

Canara Bank launches limited period attractive offer for Home loan customers

SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target

Bedmutha Industries Ltd bags Export Tender worth 715,530.00 US$

CRISIL upgrades Meghmani Finechem's rating to CRISIL AA-/Stable

Automotive Stampings and Assemblies Ltd to set up new plant at Chakan

Kopran Ltd board to consider preferential issue on Dec 8, 2021

63 moons Technologies Ltd's stake in Tickerplant Ltd reduces to 77.51%

Antony Lara Enviro Solutions Pvt Ltd awarded Merit for Excellence in Managing MSW by CII

Yashraj Containeurs Ltd updates on plant operation

Morepen gets USFDA Approval for Fexofinadine (Allegra) Expected to start export in Q4'FY22

Dilip Buildcon Ltd receives provisional completion certificate for road project in Andhra Pradesh

KEC International wins New Orders of Rs. 1,065 crores

Onward Technologies Ltd completes acquisition of NV Pune

L&T and Kemroc ink pact to distribute latter's cutting-edge products in India

Aurionpro Payment Solutions Pvt Ltd inducts new Board Members

Hero MotoCorp expands operations in Argentina, opens dealership at Buenos Aires

JSW Steel Limited restructures US coal operations

Ashoka Buildcon Ltd emerges L1 bidder for Rs. 769.41 crore project

Hindustan Zinc Ltd board to consider interim dividend for FY2022

Adani Ports and Special Economic Zone Ltd handles 24.74 MMT cargo volume in November 2021

Ethos Limited allots rights shares, to come with IPO


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020